

## Alphagan® P (brimonidine) – First-time generic

- On September 2, 2023, <u>Apotex launched</u> an <u>AB-rated</u> generic version of Allergan's <u>Alphagan P</u> (<u>brimonidine</u>) 0.1% ophthalmic solution.
  - Alembic received <u>FDA approval</u> of AB-rated generic Alphagan P on August 1, 2023. Launch plans are pending.
- Alphagan P is approved for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Brimonidine is also available generically as <u>0.15%</u> and <u>0.2%</u> ophthalmic solutions, topical <u>gel</u>, and in combination with <u>timolol</u> as an ophthalmic solution, and as a brand ophthalmic combination brimonidine/brinzolamide (<u>Simbrinza<sup>®</sup></u>), and as an over-the-counter ophthalmic solution <u>Lumify<sup>®</sup></u>.
  - Brimonidine ophthalmic solution 0.15% and 0.2% and Simbrinza carry the same indication as Alphagan P 0.1%.
  - Brimonidine topical gel is approved as topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.
  - Brimonidine/timolol is approved for the reduction of elevated IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
  - Lumify should be used for relieving redness of the eye due to minor eye irritations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.